Lawsuit Challenges FDA Decision on VOQUEZNA Exclusivity

Phathom said BDR sued the FDA over its refusal to receive an abbreviated new drug application for VOQUEZNA and its application of the GAIN Act, which recognized 10 years of new chemical entity exclusivity through May 3, 2032. Phathom said it plans to protect its statutory exclusivities.